Community Collaboration: Application of CDK 4/6 Inhibitors in the Treatment of HR-Positive/HER2-Negative Early Breast Cancer

Community Collaboration: Application of CDK 4/6 Inhibitors in the Treatment of HR-Positive/HER2-Negative Early Breast Cancer

The goal of this activity is for learners to be better able to apply recent clinical trial data to the care of patients with early breast cancer (EBC) using innovative strategies to address barriers to optimal treatment.

  • Provider:Medscape, LLC
  • Activity Link: https://www.medscape.org/viewarticle/1000352
  • Start Date: 2024-03-11 05:00:00
  • End Date: 2024-03-11 05:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
    Nursing: 0.5 hours
  • MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
  • Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 94983.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: Medical Oncology
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.